The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Colorectal Cancer
Open accessAbstract
Prostaglandin E2 (PGE2) can stimulate tumor progression by modulating several proneoplastic pathways, including proliferation, angiogenesis, cell migration, invasion, and apoptosis. Although steady-state tissue levels of PGE2 stem from relative rates of biosynthesis and breakdown, most reports examining PGE2 have focused solely on the cyclooxygenase-dependent formation of this bioactive lipid. Enzymatic degradation of PGE2 involves the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The present study examined a range of normal tissues in the human and mouse and found high levels of 15-PGDH in the large intestine. By contrast, the expression of 15-PGDH is decreased in several colorectal carcinoma cell lines and in other human malignancies such as breast and lung carcinomas. Consistent with these findings, we observe diminished 15-Pgdh expression in ApcMin+/- mouse adenomas. Enzymatic activity of 15-PGDH correlates with expression levels and the genetic disruption of 15-Pgdh completely blocks production of the urinary PGE2 metabolite. Finally, 15-PGDH expression and activity are significantly down-regulated in human colorectal carcinomas relative to matched normal tissue. In summary, these results suggest a novel tumor suppressive role for 15-PGDH due to loss of expression during colorectal tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., & Dubois, R. N. (1998) · PubMed · Cited by 1,114
Self-citationPai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002) · Nature Medicine · doi:10.1038/nm0302-289 · Cited by 836
Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice
Liu, C. H., Chang, S.-H., Narko, K., Trifan, O. C., Wu, M.-T., Smith, E., Haudenschild, C., Lane, T. F., & Hla, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010787200 · Cited by 807
Cyclooxygenase 2: a molecular target for cancer prevention and treatment
Subbaramaiah, K., & Dannenberg, A. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00043-3 · Cited by 649
Lu, Z., Ghosh, S., Wang, Z., & Hunter, T. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00304-0 · Cited by 647
Altered eicosanoid levels in human colon cancer.
Rigas, B., Goldman, I. S., & Levine, L. (1993) · PubMed · Cited by 569
Buchanan, F. G., Wang, D., Bargiacchi, F., & DuBois, R. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302474200 · Cited by 463
Self-citationMayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K., & Ludwig, H. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2454::aid-cncr2820710805>3.0.co;2-2 · Cited by 412
Wang, D., Wang, H., Shi, Q., Katkuri, S., Walhi, W., Desvergne, B., Das, S. K., Dey, S. K., & DuBois, R. N. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.011 · Cited by 340
Self-citationProstaglandin catabolizing enzymes
Tai, H.-H., Ensor, C. M., Tong, M., Zhou, H., & Yan, F. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00050-3 · Cited by 337
Self-citationPatients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2.
Pugh, S., & Thomas, G. A. (1994) · Gut · doi:10.1136/gut.35.5.675 · Cited by 266
EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma
Messa, C., Russo, F., Gabriella Caruso, M., & Di Leo, A. (1998) · Acta Oncologica · doi:10.1080/028418698429595 · Cited by 251
Prostaglandin E2 as a mediator of fever: synthesis and catabolism
Ivanov, A. (2004) · Frontiers in Bioscience · doi:10.2741/1383 · Cited by 242
Porębska, I., Harłozińska, A., & Bojarowski, T. (2000) · Tumor Biology · doi:10.1159/000030116 · Cited by 234
Rozic, J. G., Chakraborty, C., & Lala, P. K. (2001) · International Journal of Cancer · doi:10.1002/ijc.1376 · Cited by 233
Regulation of Cyclooxygenase-2 pathway by HER2 receptor
Vadlamudi, R., Mandal, M., Adam, L., Steinbach, G., Mendelsohn, J., & Kumar, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202307 · Cited by 222
Enhancement of experimental colon cancer by genistein.
Rao, C. V., Wang, C.-X., Simi, B., Lubet, R. A., Kelloff, G. J., Steele, V. E., & Reddy, B. S. (1997) · PubMed · Cited by 193
Murphey, L. J., Williams, M. K., Sanchez, S. C., Byrne, L. M., Csiki, I., Oates, J. A., Johnson, D. H., & Morrow, J. D. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.08.019 · Cited by 169
Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus
Coggins, K. G., Latour, A. M., Nguyen, M., Audoly, L., Coffman, T. M., & Koller, B. H. (2002) · Nature Medicine · doi:10.1038/nm0202-91 · Cited by 129
Moran, A. E., Hunt, D. H., Javid, S. H., Redston, M. S., Carothers, A. M., & Bertagnolli, M. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404276200 · Cited by 113
Shao, J., Evers, B. M., & Sheng, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313276200 · Cited by 89
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
DeLong, P. A., Tanaka, T. N., Kruklitis, R. J., Henry, A. C., Kapoor, V., Kaiser, L. R., Sterman, D. H., & Albelda, S. Μ. (2003) · PubMed · Cited by 89
Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer.
Kettunen, H., Kettunen, A., & Rautonen, N. (2003) · PubMed · Cited by 76
Tai, H. (1976) · Biochemistry · doi:10.1021/bi00666a007 · Cited by 60
Self-citationGiardiello, F. M., Casero, R. A., Hamilton, S. R., Hylind, L. M., Trimbath, J. D., Geiman, D. E., Judge, K. R., Hubbard, W. C., Offerhaus, G. J. A., & Yang, V. W. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.013 · Cited by 53
Indomethacin, a COX inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation
Frenkian, M., Segond, N., Pidoux, E., Cohen, R., & Jullienne, A. (2001) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(01)00116-2 · Cited by 36
Cyclooxygenase-2 and Colorectal Cancer
DuBois, R. N. (2003) · KARGER eBooks · doi:10.1159/000071370 · Cited by 35
Self-citationCho, H., & Tai, H. (2002) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00352-1 · Cited by 34
Self-citationFrontiers in cancer prevention research.
Sabichi, A. L., Demierre, M., Hawk, E. T., Lerman, C. E., & Lippman, S. M. (2003) · PubMed · Cited by 33
Nandy, A., Jenatschke, S., Hartung, B., Milde‐Langosch, K., Bamberger, A., & Gellersen, B. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310105 · Cited by 25
Cited by
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Wang, D., & DuBois, R. N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2809 · Cited by 1,793
Self-citationRegulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220
Wang, D. (2006) · Gut · doi:10.1136/gut.2004.047100 · Cited by 899
Metadata
- Authors
- Backlund, M. G., Mann, J. R., Holla, V. R., Buchanan, F. G., Tai, H.-H., Musiek, E. S., Milne, G. L., Katkuri, S., & DuBois, R. N.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 280
- Issue
- 5
- Pages
- 3217-3223
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2014306540
- Cited by
- 301
- References
- 32
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.